News & Updates
Filter by Specialty:
Hysteroscopic resection outdoes ultrasound-guided D&E for caesarean scar ectopic pregnancy
Treatment success of caesarean scar ectopic pregnancy appears to be higher with hysteroscopic resection than with ultrasound-guided dilation and evacuation (D&E), according to a study.
Hysteroscopic resection outdoes ultrasound-guided D&E for caesarean scar ectopic pregnancy
06 May 2023COVID-19 long-term sequelae and complications
Long COVID, sometimes referred to as post-acute sequelae of COVID-19, is still highly prevalent despite improved acute treatments, the emergence of newer variants, and wider vaccination coverage, says an expert at ECCMID 2023.
COVID-19 long-term sequelae and complications
06 May 2023Perampanel for idiopathic generalized epilepsy passes muster in real world
Perampanel appears to be effective and have good tolerability in patients with idiopathic generalized epilepsy treated in everyday clinical practice settings, as shown in a study.
Perampanel for idiopathic generalized epilepsy passes muster in real world
05 May 2023Immune-related AEs predict survival in cancer patients on ICI
Developing cutaneous immune-related adverse events (cirAEs) among advanced cancer patients on immune checkpoint inhibitor (ICI) appears to be a sign of longer overall survival, particularly in those with melanoma, suggests a recent study.
Immune-related AEs predict survival in cancer patients on ICI
05 May 2023Fluvoxamine plus budesonide helps prevent severe COVID-19
High-risk outpatients with early-onset COVID-19 who are treated with oral fluvoxamine plus inhaled budesonide have a reduced incidence of severe disease that warrants advanced care, reveals a study.
Fluvoxamine plus budesonide helps prevent severe COVID-19
05 May 2023Surgery, but not chemo, may benefit patients with rare ovarian neoplasms
Good quality surgery conferred a progression-free survival (PFS) benefit for women with ovarian sex cord stromal tumours (SCST) in the first-line setting and on first and second relapse. Chemotherapy, on the other hand, had no impact on survival in the first-line or relapse setting.